Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNeurizon Therapeutics Ltd

Neurizon Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.056 AUD -0.00 ( 3.45%)
Last update at 2026-11-11T05:10:00Z
VOLUME
1231290
Market Cap
50.67M

Momentum Score

…

Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.06
Low
0.06
High
52 Week Price Range
0.05
Low
0.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Neurizon Therapeutics Ltd is an Australia-listed company (ASX: NUZ) with limited publicly available information about its operations and product pipeline. Its long-term prospects would depend on progress in any neuroscience research and development programs, successful regulatory milestones, and securing partnerships or funding, which could support value creation and make it of interest to investors seeking exposure to neurological therapeutics.
The primary investment risk is high execution and financing risk typical of early-stage biotechs, including uncertainty around clinical progress, regulatory approvals and potential equity dilution.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.06
Dividend Yield
-
Revenue TTM
17.59M
Revenue Per Share
0.03
Gross Profit TTM
17.59M
Debt / Equity
0.26
ROE
-137.94%
Net Debt
-9.38M
ROCE
-217.78%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -27.08M -16.59M -8.90M -6.21M -1.71M
Net income -10.72M -16.59M -7.67M -6.21M -1.71M
Selling general administrative 3.95M 6.80M 2.81M 4.30M 4.74M
Selling and marketing expenses 2.75M - - - -
Gross profit 17.59M - - 2.04M 3.07M
Reconciled depreciation - - 0.00M 0.33M 0.31M
Ebit -27.76M -18.48M - - -
Ebitda -27.75M -18.48M - - -
Depreciation and amortization 0.00M 0.00M - - -
Operating income -27.76M -18.48M -6.66M -3.70M -2.75M
Other operating expenses 27.76M 18.48M - - -
Interest expense 0.74M - - 0.08M 0.09M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - - 0.02M 0.08M 0.00M
Net interest income - - 0.02M -0.00M -0.09M
Income tax expense -16.36M - - - -
Total revenue 17.59M - - 2.82M 3.38M
Total operating expenses 27.75M 18.48M - - -
Cost of revenue 0.00M - - 0.79M 0.31M
Total other income expense net 0.67M 1.88M -2.27M -2.51M 1.13M
Net income from continuing ops - - -8.90M -6.21M -1.71M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 23.70M 4.36M 11.12M 6.13M 10.08M
Intangible assets - 0.00M - 3.11M 3.11M
Other current assets 0.40M 0.20M 1.14M 0.08M 0.02M
Total liab 10.97M 1.54M 0.90M 2.24M 2.23M
Total stockholder equity 12.73M 2.82M 10.23M 3.89M 7.84M
Other current liab 3.86M - 0.04M - -
Common stock 98.97M 78.80M - - -
Capital stock - - 69.94M 57.63M 55.34M
Retained earnings -86.96M -75.98M -64.13M -56.46M -50.25M
Cash 12.69M 4.16M 9.71M 2.71M 2.42M
Total current liabilities 10.95M 1.53M 0.90M 1.35M 1.17M
Net debt -9.38M - - - -
Short term debt 3.31M 0.00M - - -
Short long term debt - - - - 0.21M
Short long term debt total 3.31M - - - -
Property plant equipment - 0.00M - - -
Total current assets 23.69M 4.36M 11.12M 3.02M 3.73M
Short term investments 0.02M - - - -
Net receivables 10.57M 0.00M 0.02M 0.23M 0.19M
Inventory - - - - 1.04M
Accounts payable 3.79M - 0.83M 0.93M 0.60M
Accumulated other comprehensive income 0.72M - - - -
Non current assets total 0.01M - 0.00M 3.11M 6.35M
Capital lease obligations - - - 1.05M 1.17M
Long term debt total - 0.00M - - -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -1.17M -0.03M -0.04M
Total cashflows from investing activities -0.01M -0.02M - - -
Total cash from financing activities 23.51M 8.76M 13.34M 1.89M 0.77M
Net income -10.72M - -7.67M -6.21M -1.71M
Change in cash 8.53M -5.55M 7.01M 0.29M -0.60M
Begin period cash flow 4.16M 9.71M 2.71M 2.42M 3.02M
End period cash flow 12.69M 4.16M 9.71M 2.71M 2.42M
Total cash from operating activities -15.07M -14.29M - - -
Issuance of capital stock - - 13.31M 2.24M 0.72M
Depreciation 0.00M - - - -
Change to account receivables -10.41M - - - -
Other cashflows from financing activities - -0.04M - - -
Capital expenditures 0.01M 0.00M 0.00M 0.03M 0.04M
Change in working capital -4.68M - - - -
Other non cash items 0.33M -14.29M - - -
Free cash flow -15.08M -14.29M -5.17M -1.60M -1.38M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NUZ
Neurizon Therapeutics Ltd		 -0.00
3.45%		 0.06 - 5.33 2.88 4.04 8.72 -22.59
CSL
CSL Ltd		 0.95
0.47%		 201.68 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 0.22
1.59%		 14.02 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.24
0.99%		 23.96 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.05
2.40%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Neurizon Therapeutics Ltd

Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia. Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

385 Bourke Street, Melbourne, VIC, Australia, 3000

61 3 9692 7222

https://www.neurizon.com

Name Title Year Born
Dr. Michael Thurn Ph.D. MD, CEO & Director NA
Mr. John Clark Chief Operating Officer NA
Dr. Nicky Wallis Chief Scientific Officer NA
Ms. Fiona Milner General Manager of Epichem Pty Ltd NA
Dr. Gary Pitt Head of Chemistry NA
Dr. James Rixson Head of Production NA
Dr. Herbert Brinkman Head of Manufacturing NA
Mr. Stefan Ross Company Secretary NA
Ms. Lidija Damjanovic Head of Marketing & Corporate Affairs NA
Dr. Chris Freitag M.D. Chief Medical Advisor 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…